| Abiraterone |
| (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol |
| (CAS 154229-19-3) |
 |
| Description： |
Abiraterone is a drug used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) -- i.e., prostate cancer not responding to androgen deprivation or treatment with antiandrogens. It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. Cadila Pharmaceuticals has recently started marketing Abiraterone acetate under the trade name Abretone.
After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011.[1][2] In Phase III trials, it extended median survival to 14.8 months versus 10.9 months placebo, and the trial was stopped because of the successful outcome. |
| Product No. |
KT00023 |
| Product Name |
Abiraterone |
| Synonyms |
|
| Formal Name |
(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol |
| CAS Number |
154229-19-3 |
| Molecular Formula |
C24H31NO |
| Formula Weight |
349.51 |
| Formulation |
|
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Abiraterone acetate
Anastrozole
Clarithromycin
Cobicistat
Dafadine-A |
|
